Bionomics Limited (BNO.AX)
| Previous close | 0.0230 |
| Open | 0.0220 |
| Bid | 0.0230 x 0 |
| Ask | 0.0250 x 0 |
| Day's range | 0.0220 - 0.0240 |
| 52-week range | 0.0220 - 0.0740 |
| Volume | |
| Avg. volume | 1,333,425 |
| Market cap | 32.48M |
| Beta (5Y monthly) | 2.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)
Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challengeResults achieved statistical significance in post-hoc analysis of the full data set and in relevant subpopulations Favourable safety, tolerability and PK findings are consistent with a fast-acting non-sedating anxiolytic profileThe company is planning an End of Phase 2 (EoPh2) meeting to discuss BNC210’s late-stage SAD program 2H 2023 Webcast and conference call sch
- GlobeNewswire
Bionomics’ Half-Year Report
ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented a transformational time for Bionomics in which the Company made great strides on multiple fronts, including progress on advancing the pipeline, raising capital, and implementing strategic corporate initiatives designed to create long-term shareholder value. The Company recently completed its Phase 2
- GlobeNewswire
Quarterly Activities and Cashflow Report
ADELAIDE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 31 December 2022 (Quarter) and up to the da
